Causal AI

Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area

Retrieved on: 
Donnerstag, Mai 30, 2024
Probability, Partnership, Patient, Conditional sentence, Causal AI, EVP, Biomarker, Medicine, Causality, Pharmaceutical industry

Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.

Key Points: 
  • Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
  • This is the latest in a series of collaborative agreements between Nxera and PrecisionLife, which began in 2022.
  • The partnership aims to establish new drug targets and subsequently potential precision targeted therapies for auto-immune disorders, each linked to subgroups of patients by PrecisionLife’s mechanism-based patient stratification biomarkers.
  • PrecisionLife finds combinations of biological features that together are associated with disease risk and/or protective effects.

BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders

Retrieved on: 
Donnerstag, Mai 16, 2024
Partnership, Patient, DNA, Biology, DSM-IV codes, Organization, Machine learning, LIBD, Depression, Causal AI, Bullfrog, Gene, Medicine, Brain, Artificial intelligence, Therapy, DNA methylation, Schizophrenia, Bipolar disorder, Medical device

GAITHERSBURG, Md., May 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery and development of pharmaceuticals and biologics, today announced significant advancements in its collaboration with the Lieber Institute for Brain Development (LIBD), including the identification of potential drug targets for multiple neuropsychiatric conditions.

Key Points: 
  • GAITHERSBURG, Md., May 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery and development of pharmaceuticals and biologics, today announced significant advancements in its collaboration with the Lieber Institute for Brain Development (LIBD), including the identification of potential drug targets for multiple neuropsychiatric conditions.
  • BullFrog AI and LIBD have made remarkable progress in identifying novel subgroups between and within neuropsychiatric disorders, including major depression, schizophrenia, and bipolar disorder.
  • To prioritize these genes for wet lab validation, BullFrog AI is now applying Causal AI, a crucial step for confirming the therapeutic potential of the identified targets.
  • “This collaboration continues to yield transformative insights into the biological underpinnings of neuropsychiatric disorders,” said Vin Singh, CEO of BullFrog AI.

CoachEm Appoints Eric Richard to Board of Advisors

Retrieved on: 
Montag, Mai 20, 2024
Professional Services, Data Management, Business, Technology, Human Resources, Software, Artificial Intelligence, Competition, Science, Causal AI, Engineering, Dutchy, Senior, Growth, SPSS, CISO, HubSpot, Temperament, Central Waqf Council, Entrepreneurship

CoachEm, the pioneering AI-driven coaching execution platform, proudly announces the appointment of Eric Richard to its Board of Advisors.

Key Points: 
  • CoachEm, the pioneering AI-driven coaching execution platform, proudly announces the appointment of Eric Richard to its Board of Advisors.
  • Eric Richard brings over 25 years of impactful leadership in software development, IT, security, and operations.
  • Currently, Richard holds the position of Senior Vice President of Engineering at Dutchie and serves as an advisor for Vorlon and Nametag.
  • “CoachEm’s approach to combining coaching science with coaching execution will allow companies to realize the full potential of their frontline sales managers,” said Eric Richard.

New Alembic Product Release Revolutionizes Marketing Analytics by Proving Causality in Marketing

Retrieved on: 
Montag, Mai 6, 2024
Data Management, Technology, Professional Services, Marketing, Advertising, Communications, Search Engine Marketing, Digital Marketing, Data Analytics, Software, Artificial Intelligence, Graph, Causal AI, Alembic, Paramount, LLM, Synthetic media, Classification, Hallucination, Research, Human, Gartner, NVIDIA, AI, Medical device

By combining various AI components, composite AI aims to create systems that can understand, learn and respond in a more sophisticated manner.

Key Points: 
  • By combining various AI components, composite AI aims to create systems that can understand, learn and respond in a more sophisticated manner.
  • The final goal is to create AI systems that will effectively augment human capabilities and drive transformation across industries.
  • The application of composite and multi-model systems improves AI itself which brings us closer to that goal.
  • Alembic’s composite AI solution for marketing analytics includes seven major components:
    Contextually aware ingestion (extract, transform and load): In marketing analysis, the ability to efficiently gather, process and analyze data from various sources is paramount.

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Retrieved on: 
Montag, November 13, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Technology, Artificial Intelligence, Science, Biotechnology, Neurology, Health, World Health Organization, Multiple myeloma, NYSE, Causal AI, Prevalence, Biology, PDX, Digital twin, IND, WHO, HD, PD, Multimedia, Prostate cancer, Pharmacology, Therapy, Dementia, Drug discovery, Neurodegenerative disease, CRL, Cancer, Partnership, Biomarker, AI, ADME, HIV disease progression rates, DSM-IV codes, Pharmaceutical industry, Medical imaging, Causality (physics), Logica

Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™ , Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™ , Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
  • There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.
  • As part of the partnership, Charles River has made an equity investment in Aitia.
  • More recently, Charles River and Related Sciences announced a multi-program collaboration to apply Logica across several previously undrugged targets.

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Retrieved on: 
Montag, November 13, 2023
World Health Organization, Alzheimer's disease, Multiple myeloma, Huntington's disease, Research, NYSE, Causal AI, Prevalence, Parkinson's disease, Biology, PDX, Digital twin, IND, HD, PD, Artificial intelligence, WHO, Patient, Prostate cancer, Pharmacology, Therapy, Dementia, Drug discovery, Neurodegenerative disease, CRL, Cancer, Partnership, Biomarker, AI, ADME, HIV disease progression rates, DSM-IV codes, Flagship, Pharmaceutical industry, Medical imaging, Causality (physics), Logica, Charles River

There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.

Key Points: 
  • There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.
  • We are excited to join forces with Charles River, leveraging their decades of industry expertise in research to fuel our R&D efforts."
  • Additionally, Charles River and Aitia have signed a strategic partnership agreement, focused on the development of a patient-derived xenograft (PDX) Digital Twin to predict the best tumor models for in vivo oncology research.
  • More recently, Charles River and Related Sciences announced a multi-program collaboration to apply Logica across several previously undrugged targets.

Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia's Digital Twins to be Presented at SfN 2023

Retrieved on: 
Mittwoch, November 8, 2023
Alzheimer's Disease Neuroimaging Initiative, AD, Alzheimer's disease, PD, Genetic, Parkinson's disease, Parkinson, Conference, Digital twin, HIV disease progression rates, ADNI, Gene, Causal AI, Society for Neuroscience, Medical imaging, Disease, Causality (physics)

SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.

Key Points: 
  • SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.
  • The presentation will focus on results from two Digital Twins derived from The Alzheimer's Disease Neuroimaging Initiative (ADNI), The Parkinson's Progression Markers Initiative (PPMI) and Genetic cohort study.
  • Specifically, Aitia Gemini Digital Twins for AD and PD together identified 20 genes related to cytoskeleton disorganization demonstrating a potential mechanism for patient variability in disease progression.
  • Details of the abstract and poster presentation are as follow:

Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia's Digital Twins to be Presented at CTAD 2023

Retrieved on: 
Donnerstag, Oktober 19, 2023
AD, Biomarker, Digital twin, Clinical trial, PET, GAP, Disease, Causal AI, Failure, Medical imaging, Alzheimer's disease, Causality (physics)

Aitia's Digital Twins are computational representations of disease that capture genetic and molecular interactions that causally drive clinical and physiological outcomes.

Key Points: 
  • Aitia's Digital Twins are computational representations of disease that capture genetic and molecular interactions that causally drive clinical and physiological outcomes.
  • Specifically, Aitia Gemini Digital Twins have yielded new levels of predictive accuracy of PET positivity across different ethnoracial groups as well as various disease stages.
  • These models may result in a cost-effective and convenient approach to address the high screen failure rate in clinical trial recruitment that currently plagues Alzheimer's clinical trials.
  • This method aims to be accessible to a broader at-risk population while also examining the role of various data sources in predicting PET positivity.

Parabole.ai to Present at The ThinkEquity Conference

Retrieved on: 
Montag, Oktober 16, 2023
Knowledge, Causal AI, MOM, Interest, Conference, Supply chain, Mandarin Oriental Hotel Group, MES, Hotel, Private investigator, Princeton University

Princeton, New Jersey--(Newsfile Corp. - October 16, 2023) - Parabole.ai, Knowledge-infused Causal AI to solve the most complex problems in Supply Chain optimization, MES and MOM challenges for manufacturing enterprises, will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.

Key Points: 
  • Princeton, New Jersey--(Newsfile Corp. - October 16, 2023) - Parabole.ai, Knowledge-infused Causal AI to solve the most complex problems in Supply Chain optimization, MES and MOM challenges for manufacturing enterprises, will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.
  • Rajib Saha-CEO and Anthony Sarkis CSO will be presenting at 4:00 pm ET on October 19th.
  • Interested parties can register to attend here .
  • Members of the Parabole.ai management will also be holding one-on-one investor meetings throughout the day.

Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes

Retrieved on: 
Mittwoch, September 27, 2023
Pancreatic cancer, Causal AI, Survival, Research, Biomarker, Patient, ACS, Drug combination, American Cancer Society, Digital twin, American Cancer Society Cancer Action Network, Disease, Pharmaceutical industry, SPARK, Causality (physics)

This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer.

Key Points: 
  • This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer.
  • Pancreatic cancer, responsible for over 466,003 global deaths in 2020 according to Global Cancer Statistics , is showing promising progress.
  • The American Cancer Society's (ACS) Cancer Facts & Figures 2023 report reveals an all-time high five-year survival rate of 12% for pancreatic cancer.
  • "Our collaboration with Aitia opens new doors to cutting-edge research and development, offering hope to pancreatic cancer patients and their families.